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Estimating the degree of pulmonary hyperinflation in chronic obstructive pulmonary
disease (COPD) is not always straight forward. Standard pulmonary function tests provide
only a crude estimate of this important aspect of COPD. In addition, good patient
cooperation cannot always be achieved and therefore adds to the uncertainties with
regard to the extent of hyperinflation of the lung.
The aim of this investigation was to characterize exhaled breath condensate nitrite in
volunteers, healthy smokers, and stable COPD (GOLD-stages 0–4) and to compare this
parameter with inflammatory markers in exhaled breath condensate and with lung
function in order to test the hypothesis that elevated exhaled breath condensate nitrite
reflects hyperinflation in COPD.
We found a logarithmic correlation of exhaled breath condensate nitrite to residual volume
(r ¼ 0.75, po0.0001), total lung capacity (r ¼ 0.51, po0.0001), and thoracic gas volume
(r ¼ 0.71, po0.0001) but no correlation of exhaled breath condensate nitrite concentrations
with levels of inflammatory cytokines in exhaled breath condensate (interleukin (IL)-8, IL-1b,
IL-6, IL-10, IL-12, and tumor necrosis factor-a). Analysis of COPD subgroups revealed a
logarithmic correlation of EBC nitrite to residual volume, total lung capacity, and intrathoracic
gas volume exclusively for patients characterized by GOLD classes 2, and higher.
Our results confirm a relation of exhaled breath condensate nitrite levels and
hyperinflation measured by conventional pulmonary function tests. Investigations using
isolated lung models and cells stretched in culture also provide insight into this relation.Elsevier Ltd. All rights reserved.
971 2600; fax: +49 341 971 2609.
e (C. Gessner).
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C. Gessner et al.2272Exhaled breath condensate nitrite may be a biochemical indicator of pulmonary
overdistension.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by airflow limitation due to chronic bronchitis and/or
emphysema with lung hyperinflation which is progressive and
associated with an abnormal inflammatory response of the
lung.1 These abnormalities can be estimated by pulmonary
function tests such as forced expiratory volume in 1 s (FEV1),
total lung capacity (TLC), or residual volume (RV). Emphysema
and hyperinflation can result in the most severe functional
limitations in COPD patients. Investigation and monitoring of
hyperinflation therefore seems important and various strate-
gies for lung volume reduction in COPD have been designed
such as inhaled bronchodilators, lung volume reduction surgery
and possibly endobronchial valve placement.
Estimating the extent of hyperinflation by pulmonary
function tests is not exact and assumes that patients can
cooperate well. Standard pulmonary function tests still provide
only a rough estimate of the extent of hyperinflation. In a
recent study, Smith et al.2 were able to demonstrate improved
asthma control in patients monitored by FENO, a biochemical
marker. Exhaled breath condensate (EBC), an entirely different
method, is also a non-invasive way of monitoring respiratory
disease. This technique has been used, e.g. in asthma and COPD
for measurements of cytokines, pH, leukotrienes, isoprostanes
or H2O2.
3–5 However, the evaluation of markers in EBC may be
useful for purposes other than the characterization of
inflammation. We have previously reported a strong correlation
of EBC nitrite and tidal volume in mechanically ventilated
patients, while at the same time, EBC nitrite and inflammatory
cytokines were not statistically related. This observation led us
to the hypothesis, that EBC nitrite is increased when the lung is
more distended and may indeed indicate the extent of
mechanical stress prevailing in the lung.6 This hypothesis was
supported by our observation of increased nitrite release into
the alveolar compartment in isolated lungs ventilated with a
high volume versus a low volume in rabbits,7 and by recent
findings, demonstrating nitrite accumulation in the supernatant
of increasingly distended alveolar type II cells in vitro.8
If EBC nitrite is really an indicator of distension and/or
mechanical stress in the lung, one should be able to
demonstrate increased EBC nitrite in case of hyperinflation
as it occurs in COPD. In this study, we therefore character-
ized EBC nitrite in volunteers, healthy smokers, and stable
COPD patients. Levels of EBC nitrite were compared to
levels of inflammatory cytokines in EBC and to lung function
tests in order to test the hypothesis stated above.Methods
Study subjects and clinical scores
EBC was collected from stable COPD patients, smokers, and
healthy volunteers. Stable COPD was defined by the lack ofsymptoms typical for an acute exacerbation and no need
for a change in medication for at least 8 weeks prior
to presentation. The following populations were exa-
mined: (a) COPD patients, GOLD-stage 0 (n ¼ 8), (b) COPD
patients, GOLD-stage 1 (n ¼ 13), (c) COPD patients,
GOLD-stage 2 (n ¼ 25), (d) COPD patients, GOLD-stage 3
(n ¼ 15). (e) COPD patients, GOLD-stage 4 (n ¼ 16), (f)
apparently healthy smokers (HS; n ¼ 18), (g) apparently
healthy non-smokers (VOL; n ¼ 17). Patients’ characteristics
are depicted in Table 1. All patients with COPD were non-
smokers for at least 1 year, according to their own saying.
Pulmonary function tests were performed on the day
of EBC collection by bodyplethysmography with MasterLab
Pro Version 4.2 (MasterScreen Body, ViaSys, Hoechberg,
Germany).
COPD patients were classified according to current
recommendations (GOLD1; update 2004). No patient in this
series was treated with oral or inhaled steroids, because in
former investigations, we found reduced cytokine levels in
EBC from COPD patients treated with inhaled steroids
indicating an anti-inflammatory influence of inhaled
steroids in these patients.5 Patients with COPD stage I were
treated with a short acting bronchodilator. Patients with
COPD equivalent to GOLD-stages 2 and higher were treated
with one or more long-acting bronchodilators such as
salmeterol, formoterol, or tiotropium. Several patients
were also treated with theophylline in addition to the
long-acting bronchodilator. Therapy was directed according
to current guidelines. IRB approval for this investigation
was obtained from the Ethics Committee of the University
of Leipzig.EBC collection and markers
EBC was collected for 20min during regular breathing
through a mouth piece of the EcoScreens (Jaeger/ViaSys,
Hoechberg, Germany) as previously described.9 All EBC
samples were examined for amylase activity (alpha-Amylase
ESP1491300 kit; Boehringer Mannheim, Germany) in order to
exclude contamination by saliva. EBC protein concentration
was measured using the Micro-BCA-Protein-Assay (Pierce,
Rockford USA; detection limit: 0.5 mg/mL).EBC nitrite
EBC and BALF nitrite concentrations were determined
photometrically using the GRIESS reaction.10,11 Four hun-
dred microliters of GRIESS reagent was added to 300 mL of
EBC. Absorption was read on a photometer at 550 nm.
Detection limit in this study was 0.2 mM, which was
comparable to that reported by other authors.12 All samples
were measured in duplicate.
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Table 1 Patients’ characteristics.
Patients Controls
(VOL)
Smokers
(HS)
COPD stage
0
COPD stage
1
COPD stage
2
COPD stage
3
COPD stage
4
Total number 17 18 8 13 25 15 16
Age (mean7S.D.) 60.5714.7 58.3712.4 60.979.7 61.1714.1 66.2712.0 65.4713.4 66.678.6
Sex
Male 11 10 5 10 16 11 14
Female 6 8 3 3 9 4 2
Smoking statusy Non-smoker Smoker Ex-smoker Ex-smoker Ex-smoker Ex-smoker Ex-smoker
Pack years 0 3077 3375 3179 3377 3578 3479
FEV1 (L) 3.4570.80 3.3470.97 2.5870.49 2.2270.60 1.4870.46 1.1670.26 0.7470.15
FEV1 (%/predicted) 96.9713.8 90.2711.9 89.8710.3 88.377.41 63.178.40 40.974.69 27.575.46
FVC (L) 3.9871.02 3.8871.08 3.4270.60 3.6770.78 2.6270.74 2.3970.65 1.8270.54
FVC (%/predicted) 92.4712.6 83.8716.1 85.8713.6 78.8712.3 77.7712.2 64.1713.5 49.7712.6
FEV1/FVC (%) 88.975.47 86.073.72 75.372.40 59.976.50 56.978.44 51.4711.1 42.577.53
RV (L) 1.5970.36 1.8070.63 3.2270.68 3.0271.02 3.4270.91 4.1870.97 5.0271.36
RV (%/predicted) 100.7725.2 99.1722.3 134.2727.5 137.9734.3 151.8732.6 171.7740.6 210.2767.6
TLC (L) 5.6571.07 6.0271.55 6.8970.69 6.7071.49 6.1171.31 6.6471.48 6.9571.65
TLC (%/predicted) 96.3712.8 97.9716.4 97.877.95 103.2718.1 105.8718.1 106.1716.7 110.6730.6
ITGV (L) 3.0070.59 3.2570.90 4.4470.90 3.8471.06 4.0670.98 4.8471.16 5.5271.28
ITGV (%/predicted) 105.4721.6 98.4716.9 116.4728.1 125.8723.4 129.2727.8 140.3729.1 170.1765.7
Protein in EBC (median;
range) (mg/mL)
11.4;
7.33–24.54
11.5;
5.69–26.40
9.54;
4.98–16.80
9.45;
4.64–24.54
9.94;
3.01–30.73
12.83;
1.90–15.90
10.24;
5.69–26.40
All data are shown as mean7S.D.
p40.05 (no significant difference between investigated groups) in ANOVA test (LSD).
ySmoking was defined as current smokers or ex-smokers that discontinued smoking no longer than 12 months, non-smoking as no
smoking longer than 1 year.
EBC nitrite in COPD 2273Cytometric bead array
A multiplex fluorescent bead immunoassay (cytometric bead
array (CBA) Becton Dickinson, San Jose, USA) was adapted to
analysis in breath condensate for the detection of cytokine
concentrations. A mixture of six bead populations with
distinct fluorescence intensities coated with capture anti-
bodies specific for IL-8, IL-1b, IL-6, IL-10, TNF-a, and
IL-12p70 proteins were incubated with 2mL of breath
condensate lyophilized and reconstituted with 50 mL of
ddH2O. All samples were prepared in duplicate. Cytokines
in EBC samples and recombinant standards bound to capture
beads were detected by PE-conjugated detection antibodies
in a flow cytometer (FACS CaliburTM, Becton Dickinson) as
described and validated recently.5,13
Statistical analysis
Statistical analysis was performed with the SPSS software
package (SPSS Inc., Chicago, USA). Because a scatter plot
demonstrated sigmoid relationships in the analyses of
nitrate and pulmonary function tests, the x-axis was
transferred to logarithmic scale and a logarithmic regression
analysis was performed (Figs. 2 and 3). Linear regression was
used to investigate the correlation of EBC nitrite and EBC
cytokines because no sigmoid or exponential relation was
obvious in scatter plots. A comparison of patient groups was
performed using the Kruskal–Wallis and Mann–Whitney tests.
Statistical significance was accepted at the 5% level.Results
Patients’ characteristics
Patients’ characteristics are listed in Table 1.
General exhaled breath condensate characteristics
None of the condensate samples exhibited amylase concen-
trations measurable with the assay used. Therefore, a
relevant saliva contamination can be excluded.14,15 The
mean total protein concentration in EBC for all groups is
shown in Table 1. No significant differences were observed
between the groups investigated (p ¼ 0.14). The range of
protein concentrations in EBC samples was comparable to
previous investigations.5,9
EBC nitrite levels in the different patient groups
Mean EBC nitrite differed significantly between COPD
patients and both the HS group (3.32 mM; 1.62–6.77 mM;
median; range) or the VOL group of individuals (3.48 mM;
1.19–5.57 mM). EBC nitrite reached highest levels in the
COPD stage four groups of patients (12.22 mM;
4.23–62.36 mM) with decreasing mean values in groups of
patients with less severe COPD (COPD 3: 6.61 mM;
2.66–14.23 mM; COPD 2: 5.47 mM; 1.29–15.79 mM; COPD 1:
4.82 mM; 2.53–9.74 mM; COPD 0: 3.64 mM; 2.12–6.69 mM;
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C. Gessner et al.2274Fig. 1). Nitrite was detectable in all samples examined.
Reproducibility was analyzed in subgroups of (a) 21
volunteers and (b) 21 COPD patients in whom EBC nitrite
was measured as triplet and the single measure intraclass
correlation was performed. For volunteers, the single
measure intraclass correlation was 0.914 (po0.0001), and
for COPD patients, the single measure intraclass correlation
was 0.994 (po0.0001).
EBC nitrite and pulmonary function tests
Lung function characteristics of the different patient groups
are shown in Table 1 (FEV1, FVC, FEV1/FVC, RV, TLC, and
ITGV). Table 2 summarizes the correlations between EBC
nitrite concentration and pulmonary function tests for COPD
stage 1–4 and all COPD patients. EBC nitrite was closely
correlated with residual volume (RV [L]), total lung capacity
(TLC [L]), intrathoracic gas volume (ITGV [L]), and theN
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Figure 1 Nitrite levels in COPD patients (GOLD-stages 0–4)
compared with healthy smokers and volunteers. Data in box
blots are median725/75% (box) and 5/95% confidence inter-
vals, with outlying data points indicated as closed circles.
Table 2 Correlation of EBC nitrite with lung function paramet
Parameter Correlation of EBC nitrite with lung function para
COPD stage 1 COPD stage 2 COPD
r p r p r
FVC (L) 0.10 0.75 0.27 0.18 0.38
FEV1 (L) 0.08 0.80 0.17 0.42 0.02
RV (L) 0.45 0.12 0.68 0.0002 0.72
RV/TLC 0.35 0.23 0.28 0.18 0.25
TLC (L) 0.36 0.23 0.63 0.0007 0.65
ITGV (L) 0.42 0.15 0.72 0.0001 0.73
Numbers in italic are significant.RV/TLC ratio. EBC nitrite concentration was not correlated
to forced vital capacity (FVC [L]) or the volume exhaled
during the first second of a forced expiratory maneuver
(FEV1 [L]) in the COPD patient group. A subgroup analysis of
HS and VOL individuals revealed no correlation with respect
to all of the pulmonary function tests investigated in this
study. Patients with COPD stages 2, 3, and 4 exhibited a
significant logarithmic correlation of EBC nitrite with RV,
TLC, and ITGV (Table 2). Patients of COPD stage 4
exclusively exhibited a weak correlation with FVC in
addition to the indicators of pulmonary hyperinflation
(Table 2).
The logarithmic type of relationship of EBC nitrite to RV
(y ¼ 1.29 ln x+1.08, r ¼ 0.75, po0.0001) and to RV/TLC
(y ¼ 12.33 ln x+29.01, r ¼ 0.62, po0.0001) is depicted in
Fig. 2. The correlations of EBC nitrite with TLC
(y ¼ 0.86 ln x+4.96, r ¼ 0.51, po0.0001) and of EBC nitrite
with ITGV (y ¼ 1.07 ln x+2.37, r ¼ 0.71, po0.0001) are
depicted in Fig. 3. The observation of increasing EBC
nitrite levels with increasing extent of static hyperinflation
became more evident in more advanced stages of COPD
(Table 2).
Inflammatory cytokines in EBC and EBC nitrite
Levels of cytokines in EBC were different among the three
patient groups (VOL, HS, COPD). The highest levels of all
cytokines, except for IL-10, were found in the HS group and
were all significantly higher compared to the stable COPD
group as well as the healthy volunteers (for all cytokines:
po0.05; Fig. 4). IL-1b was the only cytokine that differed
significantly between stable COPD patients and healthy
volunteers (po0.004; Fig. 4). The analysis of COPD
subgroups (GOLD levels) did not reveal significant differ-
ences with respect to any EBC cytokine levels (data not
shown).
No relevant correlation was observed between EBC nitrite
and EBC cytokines (IL-8: r ¼ 0.04, p ¼ 0.69; IL-1b: r ¼ 0.03,
p ¼ 0.72; IL-6: r ¼ 0.04, p ¼ 0.69; IL-10: r ¼ 0.02, p ¼ 0.82;
IL-12p70: r ¼ 0.03, p ¼ 0.74; TNF-a: r ¼ 0.01, p ¼ 0.89).
This was also true when EBC nitrite was correlated to EBC
cytokines normalized to protein concentration in EBC (data
not shown). Considering, that EBC cytokines likely represent
pulmonary or airway inflammation, EBC nitrite did not
appear to be an indicator of that same process.ers in COPD patients.
meters
stage 3 COPD stage 4 All COPD patients
P r p r p
0.17 0.57 0.02 0.29 0.002
0.95 0.35 0.20 0.46 0.0001
0.003 0.86 0.0001 0.75 0.0001
0.36 0.41 0.13 0.62 0.0001
0.009 0.88 0.0001 0.51 0.0001
0.002 0.87 0.0001 0.71 0.0001
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Figure 2 Nitrite correlated logarithmically with RV (A: y ¼ 1.29 ln x+1.08, r ¼ 0.75, po0.0001) and the ratio of RV to TLC
(B: y ¼ 12.33 ln x+29.01, r ¼ 0.62, po0.0001).
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Figure 3 Nitrite correlated logarithmically with TLC (A: y ¼ 0.86 ln x+4.96, r ¼ 0.51, po0.0001) and ITGV (B: y ¼ 1.07 ln x+2.37,
r ¼ 0.71, po0.0001).
EBC nitrite in COPD 2275Correlation of EBC cytokines with pulmonary
function tests
No significant correlation was observed between any of the
pulmonary function tests (FEV1, FVC, FEV1/FVC, RV, TLC,
ITGV) and the levels of cytokines in EBC in the entire patient
group, the same was true for COPD or healthy subgroups
(data not shown).Discussion
Our study was aimed at investigating the relationship of EBC
nitrite and pulmonary hyperinflation. For that purpose,
EBC nitrite was analyzed in healthy individuals, smokers
without any sign of lung disease, and stable COPD in GOLD-
stages 0–4 and was correlated with pulmonary function tests
and with inflammatory cytokines in breath condensate. We
chose to measure nitrite and cytokine profiles in exhaled
breath condensate because this material is collected non-
invasively and in addition was thought to correlate best ifthe process of generation of cytokines and EBC nitrite were
identical.
COPD is characterized by airflow limitation due to
airway inflammation, constriction and collapse in the
presence of emphysema. The extent of limitation is usually
monitored by pulmonary function tests such as FEV1, FVC,
RV, or TLC. However, these parameters require patient
cooperation and exhibit considerable variability.16,17 By
virtue of their functional nature, they also represent only
one aspect of the disease and do not allow drawing any
conclusion on biochemical processes such as cellular
integrity, inflammation or proliferation. In contrast, mea-
suring parameters in exhaled breath condensate has
recently been shown to be useful for the characterization
of inflammation in asthma2 and in COPD.5,18 In this
investigation, we could also show differences in cytokine
analysis in EBC when comparing volunteers, healthy smo-
kers, and stable COPD patients which confirms these
previous data.5
The major finding in our study is a logarithmic correlation
of pulmonary function tests RV, ITGV, TLC, and RV/TLC with
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Figure 4 Cytokines in EBC of patients in COPD compared to healthy smokers and volunteers. Data in box blots are median725/75%
(box) and 5/95% confidence intervals, with outlying data points indicated as closed circles.
C. Gessner et al.2276EBC nitrite. The strongest correlations were observed
between EBC nitrite and RV (r ¼ 0.75), as well as EBC
nitrite and ITGV (r ¼ 0.62), two markers used to describe
the extent of hyperinflation, e.g. in obstructive lung
disease. The analysis of subgroups according to the recently
propagated GOLD classification revealed elevated EBC
nitrite levels in COPD stage 2 or higher (Table 2). Thisobservation correlates well with the clinical observation of
increased emphysema and hyperinflation in these COPD
stages (GOLD classification).19 The reason for the correlation
of EBC nitrite levels with pulmonary function tests indicating
hyperinflation most likely is distension of lung parenchyma
leading to increased release of NO. This hypothesis is
supported by our observation of a lack of correlation of
ARTICLE IN PRESS
EBC nitrite in COPD 2277EBC nitrite with inflammatory cytokines in breath conden-
sate and from previous investigations in patients with
ALI/ARDS.6 In this group of mechanically ventilated pa-
tients, we reported a strong correlation of tidal volume
(adapted to ideal body weight) and EBC nitrite. Similar
findings have also been reported by other authors demon-
strating a relation between pulmonary nitric oxide release
and mechanical stimuli resulting from e.g. pulmonary artery
or venous pressure elevation or from high frequency
oscillatory ventilation.20,21 Finally, we have demonstrated
increased levels of nitrite in BAL fluid of isolated rabbit lungs
ventilated with increased tidal volumes7 and a direct
release of nitrite from mechanically stretched rat alveolar
type II cells in primary culture when compared to cells under
static conditions.8 Apoptosis of structural cells in the lung
has recently been recognized to be an important aspect in
the pathogenesis of COPD.22 Particularly in end-stage
emphysema, a significant increase in apoptotic alveolar
epithelial cells without a concomitant increase in prolifera-
tion was observed by Calabrese et al.23 Mechanical over-
distension of alveolar cells might be one reason for the
observed increase in apoptosis.
Several lines of investigations therefore lead to the
conclusion of increased mechanical distension of the lung
resulting in increased release of NO being conver-
ted to nitrite in an aqueous environment. It was shown
by Ho et al. that nitrite levels in EBC did not correlate
with NO in exhaled air.24 Furthermore, the authors stated
that nitrite measurements in EBC were more useful than
exhaled NO. The reasons for these differences between
nitrite in EBC and exhaled NO have not yet been elucidated.
A contamination of NO from the mouth may be a possible
reason.
The biological function of distension-induced nitric oxide
remains unclear. However, it has been reported that both
nitric oxide and a NO donator (L-arginin) protect alveolar
type II epithelial cells from apoptosis following mechanical
overdistension.25,26 In addition, nitric oxide may induce a
selective pulmonary vasodilatation with improved perfusion
of well ventilated alveoli, reduced intrapulmonary shunt
volume and improved oxygenation.27–29
Nitrite, generated by nitric oxide in aqueous media, has
been regarded to be primarily a marker of inflammation by
several authors.30–32 However, pulmonary inflammation does
not seem to be the major determinant of EBC nitrite in our
study for several reasons: (i) EBC nitrite does not signifi-
cantly correlate with pro-inflammatory cytokines IL-1b, IL-6,
IL-8, IL-10, IL-12, and TNF-a in EBC. (ii) None of the patients
described in this study suffered from an acute COPD
exacerbation. (iii) The strong relation of EBC nitrite and
pulmonary function tests indicative of pulmonary hyperin-
flation (RV, ITGV, RV (% of TLC) was only observed in COPD
subgroups with patients of stage 2 or higher but not in e.g.
smokers with inflammation detected by elevated cytokines
in breath condensate.
Several uncontrolled factors may have influenced our
results. Nitrate levels can be influenced by dietary nitrate
intake. Our patients did not receive a controlled diet but
were nonetheless inpatients on comparable dietary plans. In
addition, oral NO contamination may influence nitrate levels
in EBC. However, it appears unlikely that the correlations of
EBC nitrate levels with pulmonary function tests indicativeof pulmonary hyperinflation were indeed caused by oral
contamination.33
An increasing number of papers recently indicate the
usefulness of EBC as a source of biochemical information
from the lung.34 However, validation of the information
obtained will determine the use of this potential diagnostic
tool in the future. For the purpose of estimating the extent
of hyperinflation of the airways/lung in COPD, EBC nitrite
appears to perform well and might supplement monitoring
pulmonary function tests allowing for instance the early
diagnosis of hyperinflation-associated stress in the lung.
Overdistension may induce apoptosis of cells of the alveolar
wall and promote the generation of emphysema in the
setting of COPD.35 Further evaluation of EBC nitrite in COPD
and other situations with presumed mechanical stress in the
lung may help to reveal the pathogenetic role of mechanical
stress in lung disease and in monitoring therapeutic
interventions.
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